Farther Finance Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.13M Sell
12,482
-1,557
-11% -$130K 0.01% 1026
2026
Q1
$1.14M Buy
14,039
+716
+5% +$59K 0.01% 887
2025
Q4
$1.14M Buy
13,323
+1,008
+8% +$82.7K 0.01% 824
2025
Q3
$958K Buy
12,315
+1,361
+12% +$106K 0.01% 746
2025
Q2
$857K Buy
10,954
+2,146
+24% +$160K 0.02% 663
2025
Q1
$633K Buy
8,808
+7,013
+391% +$502K 0.02% 678
2024
Q4
$133K Sell
1,795
-1,286
-42% -$90K ﹤0.01% 1187
2024
Q3
$203K Sell
3,081
-3,302
-52% -$240K 0.01% 985
2024
Q2
$576K Buy
6,383
+4,947
+344% +$438K 0.03% 440
2024
Q1
$135K Buy
1,436
+448
+45% +$37.6K 0.01% 841
2023
Q4
$75.3K Buy
988
+255
+35% +$17.7K 0.01% 892
2023
Q3
$50.8K Buy
733
+279
+61% +$22.4K 0.01% 767
2023
Q2
$42.8K Buy
454
+44
+11% +$3.82K 0.01% 728
2023
Q1
$33.9K Buy
410
+75
+22% +$5.89K 0.01% 727
2022
Q4
$25K Buy
+335
New +$25.8K 0.01% 665

Other funds holding EW

Farther Finance Advisors's EW Position: Q2 2026 in Review

Farther Finance Advisors reduced its Edwards Lifesciences (EW) stake by 11% in Q2 2026, selling an estimated $130K and leaving 12,482 shares worth $1.13M. The position accounts for 0.01% of the portfolio, ranked #1026.

Farther Finance Advisors first reported a position in EW in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.14M in Q1 2026. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Farther Finance Advisors held 12,482 shares of Edwards Lifesciences worth $1.13M as of Q2 2026.
  • Farther Finance Advisors sold 1,557 Edwards Lifesciences shares in Q2 2026, an estimated $130K.
  • Edwards Lifesciences made up 0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #1026 holding.
  • Farther Finance Advisors first reported a position in Edwards Lifesciences in Q4 2022 and has held it in 15 quarters since.
  • Farther Finance Advisors's Edwards Lifesciences position peaked at $1.14M in Q1 2026.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.